IDEAYA Biosciences', a developmental biotech, valuation declined over 50% since mid-2024. Check out why I'm coming away with ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.